aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, Nov. 18, 2022 (GLOBE NEWSWIRE) — aTyr Pharma, Inc. (Nasdaq:LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the Compensation Committee of aTyr’s Board of Directors has granted four employees nonstatutory stock options to purchase an aggregate of 13,200 shares of its common stock, each with an exercise price of $2.38 per share, which is equal to the closing price of aTyr’s common stock on the Nasdaq Capital Market on November 16, 2022, the effective date of the grants. These stock awards were granted as an inducement material to the new employees entering into employment with aTyr in accordance with Nasdaq Listing Rule 5635(c)(4) and were made pursuant to the aTyr Pharma, Inc. 2022 Inducement Plan.
Related news for (LIFE)
- Top Biotech Stocks to Watch Now: Momentum, Milestones & Market Breakouts
- aTyr Pharma Announces Howard University President Emeritus Dr. Wayne A. I. Frederick as Advisor
- aTyr Pharma Presents Poster Demonstrating Preclinical Effects of Efzofitimod in Rheumatoid Arthritis and Rheumatoid Arthritis-Associated ILD at the ACR Convergence 2023
- aTyr Pharma Announces Commencement of Public Offering of Common Stock
- European Commission Grants Orphan Drug Designation for aTyr Pharma’s Efzofitimod for Treatment of Sarcoidosis